Pharmaceutical Manufacturing of Tranexamic Acid Injection

This contract involves the pharmaceutical manufacturing of sterile, injectable tranexamic acid, produced in either vials or pre-filled syringes. The production must comply with stringent regulatory standards, including those set by the FDA, the United States Pharmacopeia (USP), and military requirements, ensuring high-quality and safe injectable products. The contract is managed by the Defense Logistics Agency under the Department of Defense and falls under the NAICS code 325412, which relates to pharmaceutical preparation manufacturing. The solicitation was posted on May 28, 2026, with a response deadline of June 3, 2026, indicating a short turnaround time for interested subcontractors to submit proposals. Although no specific set-aside designation or further organizational details are provided, the contract's focus on tranexamic acid—an important hemostatic agent used to reduce bleeding—highlights its critical role in medical and military settings. This contract supports strategic stockpiling and operational readiness by facilitating the supply of this essential injectable medication.